Avantor Stock Price, News & Analysis

Avantor (NYSE: AVTR) announced on November 19, 2025 the opening of a new Centralized Service Center in Watertown, Massachusetts to serve the Greater Boston area. The facility provides off-site support for non-core lab services including glassware washing, autoclaving, media and buffer preparation, chemical management, and logistics to help organizations reclaim lab space, reduce operational complexity, and accelerate research.

The Watertown CSC integrates digital tools, SmartShelves asset tracking, daily logistics, and scalable services for pharmaceutical, biotech, academic, medtech, and advanced materials R&D customers.

Avantor (NYSE: AVTR) appointed Mary Blenn as Executive Vice President and Chief Operating Officer, effective Nov 10, 2025.

Ms. Blenn will report to President and CEO Emmanuel Ligner and lead the company's manufacturing and supply chain operations, with responsibility for aligning the manufacturing and logistics network to growth strategy, improving efficiency and scalability, and maintaining quality and reliability for customers. She brings over three decades of global operations, manufacturing, and supply chain leadership, including senior roles at Cytiva and General Electric, with experience in M&A integration, risk management, and compliance.

Avantor (NYSE: AVTR) on October 30, 2025 launched a next-generation sterile sampling platform and pre-engineered PUPSIT assemblies to streamline bioprocessing qualification and in-process decision-making.

The suite includes NBSS (needle-based), NFSS (needle-free), EVSS (exact-volume sampling) and OmniTop, offering modular multi-sample configurations, closed-path designs, standardized bills of materials, and supplier-agnostic PUPSIT assemblies that integrate with common filtration trains to reduce line breaks, operator intervention, and setup variability.

Avantor says the products support single-use and hybrid facilities across clinical to commercial scale, aiming to improve product protection, operational safety, and speed of decisions.

Avantor (NYSE: AVTR) reported Q3 2025 results for the quarter ended September 30, 2025: net sales $1.62B (down 5.3% YoY), net loss $712M and GAAP diluted loss per share of $1.04, driven by a $785M non-cash goodwill impairment in the Distribution reporting unit.

Adjusted results included Adjusted EBITDA $267.9M, adjusted EPS $0.22, operating cash flow $207.4M, free cash flow $171.7M, and adjusted net leverage of 3.1x. The Board authorized a $500M share repurchase program. A conference call and webcast were scheduled for October 29, 2025 at 8:00 AM ET.

Avantor (NYSE: AVTR) announced a collaboration with p-Chip Corporation on October 23, 2025 to co-develop "Smart Consumables" by embedding p-Chip microtransponder technology into Avantor's laboratory and clinical consumables.

The Smart Consumables (vials, slides, cassettes, tubes, plates) will carry a unique, secure identifier to enable end-to-end traceability, automated digital process control, and compliance with Chain-of-Identity (COI) requirements for life sciences, diagnostics, bio-manufacturing and healthcare workflows, addressing demands from individualized therapies such as cell and gene treatments.

Avantor (NYSE: AVTR) announced a strategic partnership with BlueWhale Bio on Oct 15, 2025 to accelerate CAR-T manufacturing by scaling production of Synecta™ cell-derived nanoparticles (CDNPs).

The collaboration combines Avantor's bioprocessing and GMP manufacturing capabilities with BlueWhale Bio's Synecta CDNP platform, aiming to produce GMP-grade CDNP materials to shorten CAR-T expansion time and increase manufacturing capacity.

BlueWhale Bio data cited earlier cell division, higher cell yields, and fewer process interventions, and notes Synecta T1 CDNPs are used in a 3-day CAR-T clinical trial.

Avantor (NYSE: AVTR) announced a chairman transition: independent director Gregory L. Summe will become Chairman of the Board effective January 1, 2026. Current Chairman Jonathan Peacock will step down as chairman and as a director at the end of 2025 after nearly nine years of service.

Since joining the board in 2020, Mr. Summe has chaired the Nominating and Governance Committee and served on the Compensation Committee. The company referenced its recent CEO change to Emmanuel Ligner and the addition of Greg Lucier to the board as part of its current governance composition.

Avantor (NYSE: AVTR) announced on October 3, 2025 that Gregory T. Lucier has been appointed to its Board of Directors. Mr. Lucier brings more than three decades of life sciences leadership, currently serving as Executive Chairman and CEO of Corza Medical, Chairman of the Board at Dentsply Sirona, and a board member of Maravai LifeSciences. He previously served as Chairman and CEO of NuVasive and Life Technologies. The board and chairman Jonathan Peacock said Lucier’s experience will support Avantor’s focus on driving growth and profitability across its Lab Solutions and Bioscience Production segments and delivering sustainable shareholder value.